Privacy Policy
Gherici Hassaine, our advisor and former CSO of Theranyx has built 100s of stable cell lines for antibody discovery in his 20+ years career.
Over a million receptors per cell. Gherici has developed cell lines that can be switched on (tetracycline-inducible) to begin receptor expression. This makes the cell lines less toxic, hence the higher receptor count.
With 5 years of development, we have reached high accuracy in our generative models, enabling for effective target-specific library designs.
Where most rely on generic libraries, we generate de-novo target-specific libraries and focus on functional epitopes.
In our lab, we screen our target-specific libraries against cells with high receptor counts to reach a high number of binders.
The panning outputs are then sent for deep sequencing and the results are analysed to capture diverse and cross-reactive sequences. Finally, we check the shortlisted antibodies for agonistic and antagonistic functions.
We work to make things better for everyone: both on a societal level and a personal level. We will thrive, as a team, as a company and as a society by combining intellect and thoughtfulness across everything we do.
We move fast and innovate in our thinking, yet combine this agility with utter rigour and robustness. We are dedicated to delivering reliable solutions.
An ugly word for a beautiful idea. Our interdisciplinary approach goes deeper than our science. We believe that the best ideas and the most interesting conversations come from synthesising diverse expertise and experiences.
We fundamentally believe in the value of each individual and the worth of their contribution, regardless of the outcome. We thrive best in a nurturing environment, and everything we do is committed to building a supportive culture.
We have the potential to transform lives. We will not let ourselves be sidetracked in this calling. We will not fail those whose future we can save.
Former software manager in a robotics company, automated DNA synthesis workflows at Thermo Fisher Scientific, 16 years experience.
Co-developed the world’s first antibody generator. MEng Engineering Science from Oxford University, inventor on several patents, 14 years of commercial experience.
Expert in antibody drug development, biotechnology and pharmaceutical marketplaces. Leadership roles at LifeArc, the Cell and Gene Therapy Catapult and Deep Science Ventures.
30 years of commercial experience in the successful establishment, growth and exits of international life science companies as founder, CEO, NED and/or investor.
PhD in Computer Science focused on AI in medical image analysis, domain shift and representation learning. Is currently developing novel AI algorithms for in-silico antibody drug discovery.
Developed a cloud-based, machine learning pipeline for processing street view images. Built the cloud infrastructure for a new machine learning platform. Holds a BSc in Neuroscience.
Previously worked in the pharmaceutical industry and holds a Master's degree in Data Science. He is an active member of the PyData Cardiff community.
Microbiologist with broad research experience and 18 years in biotech, academic and public health settings. Isa specialises in the functional screening of candidate antibodies. Holds a PhD in Viral Immunology.
Researcher and software expert with over 17 years of experience including AI protein manipulation, deep learning and bioinformatics. Holds two patents on the prediction of immune-escape proteins.
BD&L professional with experience working with pharma, biotech, academia and government. Holds an MSc in Biochemistry. Previously completed high-throughput discovery of antibiotic adjuvants against resistant bacteria
20 years of expertise in GPCR expression, purification and the nanobody development field. Former CTO at Theranyx for 8 years. He has a PhD in cell biology.
Expert in target selection and antibody development. 15 years experience in biotech, nanotech, software, laboratory automation and venture capital. Venture Partner at DSV.
3 years experience working in Synthetic Biology. DeSci and DAO Contributor. Previously developed a novel therapeutic for spinal cord injury. Holds a BSc in Biochemistry.
Background in molecular biology, cytogenetics, and protein biochemistry. 2 years as a senior scientist at Evotec. Holds a PhD in Genetics and Molecular Biology. Post-doc generating nanobodies through ribosome display.
If you are interested in learning more about our drug discovery service, please get in touch with us using the form below.
For partnership inquiries, please email partnerships@antiverse.io.
Co-founded in 2017, our team is dedicated to engineering the future of drug discovery to change the course of people’s lives. We are passionate about what we do and the impact our discoveries have on patients across the globe.
Based in Cardiff, our expert team spans structural biology, machine learning and medicine - and together, we are striving for that next breakthrough in drug discovery.
MediCentre, Heath Park, Cardiff CF14 4UJ
.png)
